# Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

> **NCT03206931** · — · NO_LONGER_AVAILABLE · sponsor: **Bayer**

## Conditions studied

- Solid Tumors Harboring NTRK Fusion

## Interventions

- **DRUG:** Selitrectinib (BAY2731954)

## Key facts

- **NCT ID:** NCT03206931
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03206931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03206931, "Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03206931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*